Last reviewed · How we verify
Unresectable advanced or recurrent malignant pleural mesothelioma
Approved treatments
- Yervoy · Bristol-Myers Squibb
Yervoy blocks a protein called CTLA-4, which normally helps to turn off the immune system, allowing it to attack cancer cells. - Yervoy · Bristol-Myers Squibb
- Opdivo · Bristol-Myers Squibb
Opdivo works by blocking the PD-1 receptor on immune cells, allowing them to attack cancer cells.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Unresectable advanced or recurrent malignant pleural mesothelioma patent landscape — cliff calendar, originator estates, attackable patents
- Unresectable advanced or recurrent malignant pleural mesothelioma treatment landscape brief
- Unresectable advanced or recurrent malignant pleural mesothelioma treatment updates RSS
Frequently asked questions about Unresectable advanced or recurrent malignant pleural mesothelioma
What drugs treat Unresectable advanced or recurrent malignant pleural mesothelioma?
Tracked treatments include Yervoy, Opdivo.
What is the treatment for Unresectable advanced or recurrent malignant pleural mesothelioma?
Standard treatment for Unresectable advanced or recurrent malignant pleural mesothelioma includes Yervoy, Opdivo. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Unresectable advanced or recurrent malignant pleural mesothelioma patent cliff · Unresectable advanced or recurrent malignant pleural mesothelioma CI report
- Treatment: Yervoy · Bristol-Myers Squibb
- Treatment: Yervoy · Bristol-Myers Squibb
- Treatment: Opdivo · Bristol-Myers Squibb
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing